Trial shows timing matters when adding immunotherapy to chemoradiation for limited-stage small cell lung cancer

People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when immunotherapy is given plays a key role in its ability to extend survival.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup